Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

1
Player Avatar joecourt (20.06) Submitted: 9/28/2011 12:52:32 PM : Outperform Start Price: $5.87 EXEL Score: -33.87

I know I am not supposed to invest with emotion, but my father recently passed from cancer. I can only hope they find a cure, or better treatment.

Featured Broker Partners


Advertisement